Ghosh, C. C., Cournoyer, L., Liu, Y., Ballarin, A., Layman, I. B., LaPorte, J., . . . Davar, D. (2024). Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases. Journal for immunotherapy of cancer, 12(7), e008837. https://doi.org/10.1136/jitc-2024-008837
Citace podle Chicago (17th ed.)Ghosh, Chandra C., et al. "Subcutaneous Checkpoint Inhibition Is Equivalent to Systemic Delivery When Combined with Nelitolimod Delivered via Pressure-enabled Drug Delivery for Depletion of Intrahepatic Myeloid-derived Suppressor Cells and Control of Liver Metastases." Journal for Immunotherapy of Cancer 12, no. 7 (2024): e008837. https://doi.org/10.1136/jitc-2024-008837.
Citace podle MLA (9th ed.)Ghosh, Chandra C., et al. "Subcutaneous Checkpoint Inhibition Is Equivalent to Systemic Delivery When Combined with Nelitolimod Delivered via Pressure-enabled Drug Delivery for Depletion of Intrahepatic Myeloid-derived Suppressor Cells and Control of Liver Metastases." Journal for Immunotherapy of Cancer, vol. 12, no. 7, 2024, p. e008837, https://doi.org/10.1136/jitc-2024-008837.